...
机译:Digoxin和GSK2606414的组合对白血病(体外)和在体内体内的体外和中的体外和中的协同抗癌活性施加协同抗癌活性
Department of PediatricsGeneral Hospital Ningxia Medical UniversityYinchuan People's Republic of China;
Department of Pharmaceutical SciencesCollege of Pharmacy University of South FloridaTampa FL USA;
Department of Radiation OncologyUniversity of Texas Southwestern Medical CenterDallas TX USA;
Department of PediatricsGeneral Hospital Ningxia Medical UniversityYinchuan People's Republic of China;
Department of PediatricsGeneral Hospital Ningxia Medical UniversityYinchuan People's Republic of China;
Department of Colorectal SurgeryGeneral Hospital Ningxia Medical UniversityYinchuan People's Republic of China;
Department of Pharmaceutical SciencesCollege of Pharmacy University of South FloridaTampa FL USA;
Department of PediatricsGeneral Hospital Ningxia Medical UniversityYinchuan People's Republic of China;
digoxin; UPR signaling inhibitor; anticancer activity; leukemia;
机译:Digoxin和GSK2606414的组合对白血病(体外)和在体内体内的体外和中的体外和中的协同抗癌活性施加协同抗癌活性
机译:在体外和体内体外和在体内和中,通过代谢稳定性的白细胞介素-15拮抗剂肽的体内表征, 99m / sup> 99m tc标记和生物学 活动分析
机译:用于生物医学注入材料的挤出三元Zn-Mg-Zr合金的评价: 在体外体外(体外) 和 在体内vivo i> 行为
机译:新型抗癌化合物sh 30的体外和体内活性
机译:急性髓系白血病协同药物联合的临床前评价
机译:RAD001和NVP-BEZ235的组合在体内和体外均具有针对非小细胞肺癌的协同抗癌活性。
机译:RAD001和NVP-BEZ235的组合在体内和体外均具有针对非小细胞肺癌的协同抗癌活性。